When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Molar pregnancies

Последний просмотренный: 15 Sep 2025
Last updated: 18 Jan 2024

Резюме

Определение

Анамнез и осмотр

Ключевые диагностические факторы

  • first trimester of pregnancy
  • vaginal bleeding
  • unusual uterine size for gestational age
Полная информация

Другие диагностические факторы

  • early-onset preeclampsia
  • shortness of breath and respiratory distress
  • severe nausea and emesis
  • tachycardia, tremor, insomnia, and diarrhea
  • pallor
  • pelvic pain
  • uterine bleeding
Полная информация

Факторы риска

  • extremes of maternal age
  • prior molar pregnancy
  • diminished dietary fat and carotene
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • histologic exam of placental tissue
  • serum human chorionic gonadotropin (hCG)
  • pelvic ultrasound
Полная информация

Исследования, проведение которых нужно рассмотреть

  • CBC
  • serum PT, PTT
  • serum metabolic panel
  • serum thyroid-stimulating hormone (TSH)
  • blood type with antibody screen
  • CXR
Полная информация

Алгоритм лечения

Острый

singleton molar pregnancy: desiring fertility

singleton molar pregnancy: not desiring fertility

viable twin fetus: elective termination not desired

viable twin fetus: elective termination

ПРОДОЛЖЕНИЕ

following initial management: high risk of gestational trophoblastic neoplasia with completed follow up unlikely

Составители

Авторы

Antonio Braga, MD

Associate Professor

Department of Obstetrics and Gynecology

Rio de Janeiro Federal University

Department of Maternal Child

Fluminense Federal University

Rio de Janeiro

Brazil

Раскрытие информации

AB is an author of references cited in this topic.

Kevin M. Elias, MD

Assistant Professor

Brigham and Women’s Hospital

Dana Farber Cancer Institute

New England Trophoblastic Disease Center

Division of Gynecologic Oncology

Department of Obstetrics, Gynecology and Reproductive Biology

Harvard Medical School

Boston

MA

Раскрытие информации

KME has been a paid consultant for AOA Dx and received research support from Aspira Women’s Health and Abcam, Inc. KME is an author of references cited in this topic.

Neil S. Horowitz, MD

Associate Professor

Brigham and Women’s Hospital

Dana Farber Cancer Institute

New England Trophoblastic Disease Center

Division of Gynecologic Oncology

Department of Obstetrics, Gynecology and Reproductive Biology

Harvard Medical School

Boston

MA

Раскрытие информации

NSH is an author of references cited in this topic.

Ross S. Berkowitz, MD

William H. Baker Professor of Gynecology

Brigham and Women’s Hospital

Dana Farber Cancer Institute

New England Trophoblastic Disease Center

Division of Gynecologic Oncology

Department of Obstetrics, Gynecology and Reproductive Biology

Harvard Medical School

Boston

MA

Раскрытие информации

RSB is an author of references cited in this topic.

Выражение благодарностей

Dr Ross S. Berkowitz, Dr Kevin M. Elias, Dr Neil S. Horowitz, and Dr Antonio Braga would like to gratefully acknowledge Dr John Soper and Dr Emma Rossi, previous contributors to this topic. JS and ER declare that they have no competing interests.

Рецензенты

Jane Stewart, PhD, MSc

Consultant Gynecologist

Subspecialist in Reproductive Medicine

Newcastle Fertility Centre at Life

Bioscience Centre

International Centre at Life

Newcastle upon Tyne

UK

Раскрытие информации

JS declares that she has no competing interests.

Philip Savage, PhD, FRCP

Consultant in Medical Oncology

Department of Medical Oncology

Charing Cross Hospital

London

UK

Раскрытие информации

PS declares that he has no competing interests.

Aparna Sundaram, DO, MBA, MPH

Physician Consultant

Preventive Medicine

Private Practice

Atlanta

GA

Раскрытие информации

AS declares that she has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

Horowitz NS, Eskander RN, Adelman MR, et al. Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation. Gynecol Oncol. 2021 Dec;163(3):605-13.Полный текст  Аннотация

Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):86-93.Полный текст  Аннотация

Tidy, J, Seckl, M, Hancock, BW, on behalf of the Royal College of Obstetricians and Gynaecologists. Management of gestational trophoblastic disease. BJOG 2021;128: e1-e27​.Полный текст

Lok C, van Trommel N, Massuger L, et al. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020 May;130:228-40. Аннотация

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности